Agios Pharmaceuticals
AGIO
27.60
-1.16
-4.03%
Agios Pharmaceuticals
US · AGIO
#2841 by market cap
Listed 1970
27.60
-1.16
-4.03%
Periodic snapshot; not a real-time feed.
· 2026-11-20 19:30
Recent news
-
Rating change
H.C. Wainwright Maintains Agios Pharmaceuticals(AGIO.US) With Buy Rating, Maintains Target Price $55Market Newswire · 2026/11/6
-
Rating change
Truist Financial Maintains Agios Pharmaceuticals(AGIO.US) With Buy RatingMarket Newswire · 2026/8/11
-
Rating change
Truist Financial Maintains Agios Pharmaceuticals(AGIO.US) With Buy Rating, Announces Target Price $39Market Newswire · 2026/7/31
-
Rating change
H.C. Wainwright Maintains Agios Pharmaceuticals(AGIO.US) With Buy Rating, Maintains Target Price $54Market Newswire · 2026/7/13
-
Truist Financial Maintains Agios Pharmaceuticals(AGIO.US) With Buy Rating, Cuts Target Price to $35Market Newswire · 2026/11/6
-
Rating change
A Quick Look at Today's Ratings for Agios Pharmaceuticals(AGIO.US), With a Forecast Between $39 to $55Market Newswire · 2026/7/31
-
Rating change
H.C. Wainwright Initiates Agios Pharmaceuticals(AGIO.US) With Buy Rating, Announces Target Price $55Market Newswire · 2026/10/29
-
H.C. Wainwright Maintains Agios Pharmaceuticals(AGIO.US) With Buy Rating, Raises Target Price to $62Market Newswire · 2026/11/6
-
Rating change
BofA Securities Maintains Agios Pharmaceuticals(AGIO.US) With Buy Rating, Maintains Target Price $46Market Newswire · 2026/7/22
-
Rating change
Citi Maintains Agios Pharmaceuticals(AGIO.US) With Buy Rating, Maintains Target Price $52Market Newswire · 2026/10/28
-
Rating change
H.C. Wainwright Maintains Agios Pharmaceuticals(AGIO.US) With Buy Rating, Cuts Target Price to $52Market Newswire · 2026/7/22
-
BofA Securities Maintains Agios Pharmaceuticals(AGIO.US) With Buy Rating, Cuts Target Price to $48Market Newswire · 2026/11/6
-
Rating change
BofA Securities Maintains Agios Pharmaceuticals(AGIO.US) With Buy Rating, Raises Target Price to $50Market Newswire · 2026/9/21
-
Company notice
Agios Pharmaceuticals: Agios Pharmaceuticals, Inc. - Flex Position Consolidation Option Symbol: 1AGIOOCC · 2022/4/28
-
Truist Financial Maintains Agios Pharmaceuticals(AGIO.US) With Buy Rating, Maintains Target Price $35Market Newswire · 2026/11/6
-
Rating change
RBC Capital Maintains Agios Pharmaceuticals(AGIO.US) With Hold Rating, Raises Target Price to $32Market Newswire · 2026/10/9
-
Rating change
TD Cowen Maintains Agios Pharmaceuticals(AGIO.US) With Buy RatingMarket Newswire · 2026/8/4
-
RBC Capital Maintains Agios Pharmaceuticals(AGIO.US) With Hold Rating, Maintains Target Price $32Market Newswire · 2026/11/6
-
Rating change
Truist Financial Maintains Agios Pharmaceuticals(AGIO.US) With Buy Rating, Announces Target Price $37Market Newswire · 2026/10/7
-
Rating change
BofA Securities Maintains Agios Pharmaceuticals(AGIO.US) With Buy Rating, Maintains Target Price $50Market Newswire · 2026/10/6
-
Rating change
BofA Securities Maintains Agios Pharmaceuticals(AGIO.US) With Buy Rating, Raises Target Price to $46Market Newswire · 2026/7/7
-
Rating change
A Quick Look at Today's Ratings for Agios Pharmaceuticals(AGIO.US), With a Forecast Between $36 to $54Market Newswire · 2026/6/16
-
Rating change
A Quick Look at Today's Ratings for Agios Pharmaceuticals(AGIO.US), With a Forecast Between $41 to $54Market Newswire · 2026/7/8
-
Rating change
H.C. Wainwright Remains a Buy on Agios Pharma (AGIO)TipRanks · 2026/7/13
-
H.C. Wainwright Maintains Agios Pharmaceuticals(AGIO.US) With Buy Rating, Maintains Target Price $55Market Newswire · 2026/10/30
Headlines are aggregated automatically and are not independently verified or edited by our team.
Quote time 2026-11-20 19:30:06 · For reference only, not investment advice and not tailored to your situation.
Agios Pharmaceuticals discussion 0 comments